← Leaderboards
John P Konhilas
University Of Arizona
$2,673,441
Attributed
$8,020,322
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2020–23$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
Funding mix
By agency
NIH$8,020,322 · 1
By mechanism
U01$8,020,322 · 1
Top collaborators
- Meredith Hay10 shared
- Heidi M. Mansour10 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Heidi M. Mansour$4,596,984
- Timothy A Marlowe$5,077,422
- Craig C Weinkauf$6,475,434
- Christopher C Glembotski$23,681,242
- Todd W Vanderah$11,756,178
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposNeuronsAngiotensinsS DiseaseVisionPeptidesHeart FailureInflammatoryEncephalitisReceptorVascular Cognitive Impairment And DementiaClinical TrialsS Disease RiskDementiaLeadBrainAgonistImpaired CognitionS Disease Related DementiaCardiovascular DiseasesFormulationFrequenciesCerebrovascular CirculationCognitive Function
Grant awards (10)
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$1,535,000
U01 · FY2023 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$679,894
U01 · FY2023 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$1,145,632
U01 · FY2022 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$766,972
U01 · FY2022 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$48,092
U01 · FY2022 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$1,596,374
U01 · FY2021 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$380,202
U01 · FY2021 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$16,031
U01 · FY2021 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$1,506,750
U01 · FY2020 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$345,375
U01 · FY2020 · AG